Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NVCR Stock Forecast 2025-2026
$17.38
Current Price
$1.94B
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to NVCR Price Targets
+130.1%
To High Target of $40.00
+89.9%
To Median Target of $33.00
+55.4%
To Low Target of $27.00
NVCR Price Momentum
-2.1%
1 Week Change
+5.3%
1 Month Change
+5.5%
1 Year Change
-41.7%
Year-to-Date Change
-49.1%
From 52W High of $34.13
+22.7%
From 52W Low of $14.17
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Novocure (NVCR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NVCR and similar high-potential opportunities.
Latest NVCR Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, NVCR has a bullish consensus with a median price target of $33.00 (ranging from $27.00 to $40.00). Currently trading at $17.38, the median forecast implies a 89.9% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Larry Biegelsen at Wells Fargo, projecting a 130.1% upside. Conversely, the most conservative target is provided by David Nierengarten at Wedbush, suggesting a 55.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVCR Analyst Ratings
5
Buy
2
Hold
0
Sell
NVCR Price Target Range
Low
$27.00
Average
$33.00
High
$40.00
Current: $17.38
Latest NVCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 23, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $34.00 |
| Apr 16, 2025 | Wedbush | David Nierengarten | Neutral | Maintains | $27.00 |
| Apr 10, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $28.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $38.00 |
| Dec 13, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $42.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $38.00 |
| Dec 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $30.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $38.00 |
| Nov 21, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $30.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $30.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Upgrade | $30.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $18.00 |
| Jul 26, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $40.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $24.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $20.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $22.00 |
| May 2, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $22.00 |
| Apr 10, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $28.00 |
| Apr 3, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $42.00 |
| Mar 27, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $24.00 |
Novocure Ltd. (NVCR) Competitors
The following stocks are similar to Novocure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Novocure Ltd. (NVCR) Financial Data
Novocure Ltd. has a market capitalization of $1.94B with a P/E ratio of -11.1x. The company generates $621.71M in trailing twelve-month revenue with a -26.4% profit margin.
Revenue growth is +11.9% quarter-over-quarter, while maintaining an operating margin of -24.4% and return on equity of -45.5%.
Valuation Metrics
Market Cap
$1.94B
Enterprise Value
$1.71B
P/E Ratio
-11.1x
PEG Ratio
-11.6x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+11.9%
Gross Margin
+75.1%
Operating Margin
-24.4%
Net Margin
-26.4%
EPS Growth
+11.9%
Financial Health
Cash/Price Ratio
+48.0%
Current Ratio
1.5x
Debt/Equity
192.5x
ROE
-45.5%
ROA
-8.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Novocure Ltd. (NVCR) Business Model
About Novocure Ltd.
What They Do
Develops innovative cancer treatment therapies.
Business Model
The company focuses on the development and commercialization of Tumor Treating Fields (TTFields) therapy, generating revenue through the sale of its non-invasive cancer treatment devices to healthcare providers and institutions. By targeting aggressive cancers like glioblastoma and mesothelioma, Novocure aims to provide alternative treatment options that may be more effective than traditional methods.
Additional Information
Headquartered in Saint Helier, Jersey, Novocure operates globally and is committed to advancing oncology through clinical research and development. Its innovative therapies position it as a leader in the specialty cancer treatment market, with significant implications for the biotechnology and medical device sectors.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,453
CEO
Mr. Asaf Danziger
Country
Jersey
IPO Year
2015
Website
www.novocure.comNovocure Ltd. (NVCR) Latest News & Analysis
Latest News
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
13 days ago
Quick Summary
Wall Street analysts project a 91.9% upside for NovoCure (NVCR), supported by positive earnings estimate revisions, despite questions about the effectiveness of price targets.
Why It Matters
A 91.9% upside in price targets for NovoCure suggests strong growth potential, while positive earnings revisions may boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
NovoCure Surpasses Q1 Expectations
18 days ago
Quick Summary
NovoCure (NVCR) reported Q1 2025 revenue of $155 million, exceeding estimates of $146 million, reflecting strong performance in its Tumor Treating Fields therapy.
Why It Matters
NovoCure’s revenue beat expectations, signaling strong demand for its TTFields therapy, which can boost investor confidence and potentially drive stock price growth.
Source: The Motley Fool
Market Sentiment:
Positive
Why NovoCure Stock Leaped 4% Higher Today
17 days ago
Quick Summary
NovoCure (NVCR) reported positive quarterly results for Q1 2025, leading to a stock price increase of over 4%, outperforming the S&P 500's 2% rise.
Why It Matters
NovoCure's strong quarterly results and stock performance exceeding the S&P 500 indicate positive market sentiment and potential growth, attracting investor interest in the biotech sector.
Source: The Motley Fool
Market Sentiment:
Positive
Why NovoCure Stock Skyrocketed This Week
16 days ago
Quick Summary
NovoCure (NVCR) shares rose 0.11% as of 3:30 p.m. on Thursday.
Why It Matters
NovoCure's stock gaining indicates positive market sentiment, potentially reflecting investor confidence in the company's performance or upcoming developments.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
NovoCure Limited (NASDAQ: NVCR) will hold its Q1 2025 earnings conference call on April 24, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
Why It Matters
NovoCure's upcoming earnings call may reveal key financial performance and strategic developments, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Novocure (NASDAQ: NVCR) reported Q1 2025 financial results, highlighting progress in expanding its cancer therapy, Tumor Treating Fields (TTFields), following years in a single indication.
Why It Matters
Novocure's strong Q1 results and expansion into new indications signal growth potential, which can boost investor confidence and stock performance in the oncology sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NVCR Stock
What is Novocure Ltd.'s (NVCR) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Novocure Ltd. (NVCR) has a median price target of $33.00. The highest price target is $40.00 and the lowest is $27.00.
Is NVCR stock a good investment in 2025?
According to current analyst ratings, NVCR has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NVCR stock?
Wall Street analysts predict NVCR stock could reach $33.00 in the next 12 months. This represents a 89.9% increase from the current price of $17.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Novocure Ltd.'s business model?
The company focuses on the development and commercialization of Tumor Treating Fields (TTFields) therapy, generating revenue through the sale of its non-invasive cancer treatment devices to healthcare providers and institutions. By targeting aggressive cancers like glioblastoma and mesothelioma, Novocure aims to provide alternative treatment options that may be more effective than traditional methods.
What is the highest forecasted price for NVCR Novocure Ltd.?
The highest price target for NVCR is $40.00 from Larry Biegelsen at Wells Fargo, which represents a 130.1% increase from the current price of $17.38.
What is the lowest forecasted price for NVCR Novocure Ltd.?
The lowest price target for NVCR is $27.00 from David Nierengarten at Wedbush, which represents a 55.4% increase from the current price of $17.38.
What is the overall NVCR consensus from analysts for Novocure Ltd.?
The overall analyst consensus for NVCR is bullish. Out of 14 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are NVCR stock price projections?
Stock price projections, including those for Novocure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 10:25 AM UTC